The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Fear factor fades as global M&A hits seven-year high

Sun, 21st Dec 2014 08:00

By Pamela Barbaglia and Sophie Sassard

LONDON, Dec 21 (Reuters) - Chief executives got theirdeal-making confidence back in 2014, emboldened by a cleareroutlook for their businesses to take the global value formergers and acquisitions (M&A) to their highest annual levelsince 2007.

The total was boosted by a rush of large deals in thetelecoms, healthcare and consumer sectors, with transactions,some of which had been contemplated for years, promising tocause a chain reaction as rivals move to defend their territory.

In the latest example British telecoms group BT's move to buy mobile operator EE is expected to put pressure onrivals to seek their own tie-ups as fixed-line and mobilenetworks and pay-TV services converge.

"The need to stay competitive and strengthen the corebusiness is the main catalyst," said Wilhelm Schulz, head of M&A in Europe, Middle East and Africa (EMEA) at Citi.

Global deal volume to Dec. 11 hit $3.27 trillion, up 40percent from the same period last year, according to ThomsonReuters data. This was the highest level since 2007, when thetotal was $4.12 trillion during a leveraged buyout boom whichsaw private equity firms sign multi-billion-dollar cheques andload companies with debt.

In contrast deals in 2014 were mainly driven by morecautious company boards, using shares rather than debt to fundpurchases.

Executives haven't lost all their post-crisis inhibitionsand still prefer safe bets rather than bold adventures such asFrench telecoms group Iliad's attempt to buy T-MobileUS.

"The market is rewarding tried and tested deals, driven bysynergies," said Paulo Pereira, a partner at Perella Weinberg.

GEOPOLITICAL RISK

But expectations that the pace of deal-making will keep upin 2015 have taken a knock from the oil price slump anddeepening Russian economic crisis.

"The geopolitical risk remains a concern for 2015," saidGilberto Pozzi head of M&A for the EMEA region at Goldman Sachs.

"If the oil crisis further deteriorates and politicaltensions escalate, M&A activity could suffer as CEOs wouldbecome more risk averse."

So far, however, the appetite for big deals shows no signsof weakening as the quest for market supremacy persists.

Comcast Corp's $45 billion bid for Time WarnerCable will give the pair a near 30 percent share of theU.S. pay TV market, while telecoms giant AT&T is looking to acquire satellite TV provider DirecTV in a $48.5 billiondeal.

Both deals are still under review with U.S. regulators.

In Europe Lafarge and Holcim aim tocomplete their merger next year, having secured European Unionapproval, to create the world's biggest cement maker with over$40 billion in annual sales.

However, some other potentially major deals barely got offthe drawing board, such as brewer SAB Miller's approachto family-controlled Dutch rival Heineken.

"There is no stigma to deal-jumping any more," said ChrisVentresca, JP Morgan's global co-head of M&A.

"Companies have greater confidence and can withstand a bumpin the road because there is less uncertainty on theirprospects," he added.

EUROPEANS BIDDING IN AMERICA

Expanding abroad has been a key motivator this year forEuropean companies looking to escape from the continent'ssluggish economies, with the United States a prime target.

In September Germany's Siemens struck a $7.6bnall-cash deal to buy U.S.-based Dresser Rand.

"The largest world economy is open for transactions and isgrowing in a more predictable way than many other geographies,"said Severin Brizay, head of M&A in EMEA at UBS.

At the same time U.S. firms are becoming more cautious aboutEurope. "They need to see that the economies in Europe arestabilized and going up, but there is not a big consensus onthat," said Ventresca.

Some also had to think again after the U.S. Treasury movedto deter so-called "inversion" deals whereby companies weremaking acquisitions to reincorporate abroad to avoid high taxesat home.

As a result U.S. drugmaker AbbVie pulled the plugon its $55 billion deal to buy Dublin-based Shire, whilePfizer faced a UK political backlash against itsproposed $118 billion acquisition of AstraZeneca.

However, changes in U.S. tax rules so far have not killedoff further inversion deals altogether.

"Companies will always factor in minimising taxes as theyconsider the best way to structure their business. That is theirjob," said Bob Eatroff, co-head of M&A for the Americas atMorgan Stanley.

NEW BUYERS

Meanwhile in Europe the emergence of unexpected butdeep-pocketed "left-field" buyers from developing economies hasraised the stakes for some prospective Western acquirers, including private equity firms.

Buy-out firms, whose acquisitions accounted for around 8 percent of the M&A market this year, have at times struggled tocompete on price.

Chinese buyers had a particularly strong year in Europe,bankers said, targeting Germany's medium-sized manufacturingfirms and distressed assets in Southern Europe.

"China needs M&A to achieve true international expansion,beyond markets such as Brazil or Africa, and a wider access totechnology," said Pereira.

With cross-border activity on the rise, the ingredients foranother busy year are all there with bankers predicting a newwave of deals in financial services, chemicals and energy aswell as continuing consolidation in both healthcare and thetelecoms, media and technology (TMT) sector.

"Investors tend to punish idleness," said Lazard Germany'sco-head of investment banking, Ken Oliver Fritz. (Additional reporting by Mike Stone in New York and ArnoSchuetze in Frankfurt; Editing by Greg Mahlich)

More News
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 13:51

Sensodyne maker Haleon to shut UK factory with loss of 435 jobs

(Alliance News) - More than 400 jobs are to be axed at Sensodyne toothpaste and Advil painkillers firm Haleon PLC as the group revealed plans to shut its only manufacturing site in the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.